Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial
- 28 June 2011
- journal article
- research article
- Published by Wiley in Respirology
- Vol. 16 (5) , 825-835
Abstract
Background and objective: Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4‐year COPD trial.Methods: Subgroup analysis from a randomized, double‐blinded, placebo‐controlled trial of tiotropium 18 µg daily in COPD. Primary end‐point was rate of decline in FEV1. Secondary end‐points included spirometry at individual time points, health‐related quality of life (St George's Respiratory Questionnaire), exacerbations and mortality.Results: Of 5992 patients, 362 were from Asian centres (100 from Japan). Mean age 66 years, 95% men, 13% current smokers, BMI: 21 kg/m2; post‐bronchodilator FEV1: 44% predicted; St George's Respiratory Questionnaire total score: 44 units. No treatment effect was observed for rate of decline in FEV1 although annual decline was less in Asian patients. Morning pre‐bronchodilator FEV1 and forced vital capacity improved in Asian patients (P < 0.05). Tiotropium reduced number of exacerbations (rate ratio (95% confidence interval (CI)): 0.73 (0.57–0.94)). Hazard ratios (95%CI) for exacerbations and hospitalized exacerbations (tiotropium/control) were 0.81 (0.62–1.05) and 0.85 (0.61–1.19), respectively. St George's Respiratory Questionnaire total score improved by 1.5–6.1 units (P < 0.05 for months 18, 24, 30 and 36) with tiotropium. Fatal events occurred in 34 tiotropium (18.5%) and 42 control (23.6%) patients.Conclusions: In COPD patients from Asia, tiotropium improves lung function, improves health‐related quality of life and reduces exacerbations over 4 years of treatment.Keywords
This publication has 22 references indexed in Scilit:
- Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trialRespiratory Medicine, 2010
- Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trialEuropean Respiratory Journal, 2010
- Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialThe Lancet, 2009
- Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trialEuropean Respiratory Journal, 2009
- Trends in COPD mortality and hospitalizations in countries and regions of Asia‐PacificRespirology, 2008
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- COPD in AsiaChest, 2008
- Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: An Asia–Pacific perspectiveRespirology, 2005
- COPD in Japan: the Nippon COPD Epidemiology studyRespirology, 2004